BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...

New research presented this year highlighted major advances for people with hormone-receptor–positive, HER2-negative breast ...

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon ...

ARPIs used in combination with ADT in prostate cancer significantly increased the risk for cardiovascular events.

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...

The Chinorec trial reveals that combining Yervoy and Opdivo with chemoradiotherapy is safe for rectal cancer, though response rates remain unchanged.

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive mCRPC after progression on ARPIs, including patients with and without prior ...

A novel treatment approach combining neoadjuvant immunotherapy with chemoradiation showed promising results in patients with locally advanced esophageal squamous cell carcinoma (ESCC), according to ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...